Biotron Ltd Market Cap ($3.94 Million)
Market Cap & Net Worth: Biotron Ltd (BIT)
Biotron Ltd market cap. Biotron Ltd (AU:BIT) has a market capitalization of $3.94 Million (AU$5.57 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28965 globally and #1564 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotron Ltd's stock price AU$0.00 by its total outstanding shares 2785204977 (2.79 Billion). Also see BIT cash generation efficiency for how efficiently the company converts equity into cash flow.
Biotron Ltd Market Cap History (2015–2026)
Biotron Ltd market cap history from 2015 to 2026. Data shows change from $82.57 Million to $3.94 Million (-24.45% CAGR). Check today's stock price for Biotron Ltd for real-time trading data and today's change.
Biotron Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotron Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Biotron Ltd annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.26x
Biotron Ltd's market cap is 3.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $50.25 Million | $1.66 Million | -$3.09 Million | 30.28x | N/A |
| 2018 | $219.54 Million | $1.62 Million | -$1.59 Million | 135.30x | N/A |
| 2019 | $99.32 Million | $1.07 Million | -$1.61 Million | 92.58x | N/A |
| 2020 | $148.79 Million | $803.03K | -$3.58 Million | 185.28x | N/A |
| 2021 | $185.05 Million | $1.46 Million | -$3.19 Million | 126.58x | N/A |
| 2022 | $53.21 Million | $1.56 Million | -$2.78 Million | 34.14x | N/A |
| 2023 | $191.16 Million | $1.43 Million | -$3.49 Million | 133.56x | N/A |
| 2024 | $35.47 Million | $1.65 Million | -$3.44 Million | 21.56x | N/A |
| 2025 | $5.91 Million | $1.81 Million | -$318.57K | 3.26x | N/A |
Competitor Companies of BIT by Market Capitalization
Companies near Biotron Ltd in the global market cap rankings as of November 7, 2026. Also see Biotron Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Biotron Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Biotron Ltd (2015–2026)
Market capitalization of Biotron Ltd from 2015 to today. Between 2015 and today, Biotron Ltd's market cap moved from $82.57 Million to $ 3.94 Million, with a yearly change of -24.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$3.94 Million | -33.33% |
| 2025 | AU$5.91 Million | -83.33% |
| 2024 | AU$35.47 Million | -81.44% |
| 2023 | AU$191.16 Million | +259.26% |
| 2022 | AU$53.21 Million | -71.25% |
| 2021 | AU$185.05 Million | +24.37% |
| 2020 | AU$148.79 Million | +49.80% |
| 2019 | AU$99.32 Million | -54.76% |
| 2018 | AU$219.54 Million | +336.86% |
| 2017 | AU$50.25 Million | -22.02% |
| 2016 | AU$64.44 Million | -21.96% |
| 2015 | AU$82.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Biotron Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.94 Million USD |
| MoneyControl | $3.94 Million USD |
| MarketWatch | $3.94 Million USD |
| marketcap.company | $3.94 Million USD |
| Reuters | $3.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops pre… Read more